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Abstract
Most DNA viruses express small regulatory RNAs, which interfere with viral or cellular gene
expression. For adeno-associated virus (AAV), a small ssDNA virus with a complex
biphasic life cycle miRNAs or other small regulatory RNAs have not yet been described.
This is the first comprehensive Illumina-based RNA-Seq analysis of small RNAs expressed
by AAV alone or upon co-infection with helper adenovirus or HSV. Several hotspots of
AAV-specific small RNAs were detected mostly close to or within the AAV-ITR and appar-
ently transcribed from the newly identified anti-p5 promoter. An additional small RNA hot-
spot was located downstream of the p40 promoter, from where transcription of non-coding
RNAs associated with the inhibition of adenovirus replication were recently described. Par-
allel detection of known Ad and HSV miRNAs indirectly validated the newly identified small
AAV RNA species. The predominant small RNAs were analyzed on Northern blots and by
human argonaute protein-mediated co-immunoprecipitation. None of the small AAV RNAs
showed characteristics of bona fide miRNAs, but characteristics of alternative RNA pro-
cessing indicative of differentially regulated AAV promoter-associated small RNAs. Further-
more, the AAV-induced regulation of cellular miRNA levels was analyzed at different time
points post infection. In contrast to other virus groups AAV infection had virtually no effect
on the expression of cellular miRNA, which underscores the long-established concept that
wild-type AAV infection is apathogenic.
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Introduction
Adeno-associated viruses (AAV) belong to the family of parvoviruses and possess a single-
stranded DNA genome of approximately 4.7 kb. A characteristic feature of AAV is its biphasic
life cycle. In the absence of a helper virus AAV establishes latent infection and integrates into
the host genome or persist as nuclear episome [1–3]. Co-infection with a helper virus, e.g. ade-
novirus or herpesvirus results in AAV replication and progeny formation [4–8]. AAV type 2
represents the best-studied serotype and is commonly accepted as AAV prototype. The AAV2
genome contains two major open reading frames, rep and cap, which are flanked by hairpin-
structured, 145 bp inverted terminal repeats (ITRs) at either end [9]. The rep gene encodes the
four regulatory proteins Rep78 and Rep68, and N-terminally truncated versions thereof, called
Rep52 and Rep40, respectively. The AAV capsid proteins VP1, VP2 and VP3 are encoded by
the cap gene. Furthermore, cap encodes the assembly activating protein (AAP) by use of an
alternative open reading frame [10]. Early AAV2 transcription mapping only defined tran-
scripts derived from the coding AAV positive (+) strand. These mRNAs initiate at the p5, p19
or p40 promoters, named according to their relative positions on the AAV2 genome. In a total
RNA-Seq analysis, we have recently discovered transcription on the AAV negative (-) strand
opposite to the p5 promoter, indicative of non-coding RNA species [11]. In addition, we have
identified p40 promoter-associated short non-coding transcripts on the (+) strand relevant for
the inhibition of adenovirus replication [12]. Apparently, non-coding RNA species are
involved in the regulation of the AAV life cycle.
Small non-coding RNAs represent a growing class of diverse, regulatory RNAs. Of these,
microRNAs (miRNAs) and short interfering RNAs (siRNAs) represent the best-characterized
species. These RNAs are approximately 22 nucleotides in length and are processed by the cellu-
lar enzyme Dicer from longer double-stranded RNA precursors that form a distinctive, second-
ary RNA structure [13, 14]. One strand of the processed RNA duplex is loaded into the RNA-
induced silencing complex (RISC) allowing recognition of the mRNA target sequence. Mam-
malian miRNAs and siRNAs typically represent posttranscriptional inhibitors by specifically
binding to a target RNA leading to translational repression or mRNA degradation [15, 16].
Less well characterized classes of small regulatory RNAs have since been described, whose
functions are largely unknown. Of these, tRNA-derived fragments (tRFs) or microRNA-offset
RNAs (moRs) have been suggested to play a miRNA-like role in posttranscriptional gene
silencing [17, 18]. Others, such as promoter-associated RNAs (paRNAs) appear to be specifi-
cally involved in regulating promoter activity [19].
Most DNA virus genera and also certain RNA viruses express small non-coding RNAs [20,
21], but often the molecular function has not been fully defined. Adenovirus (Ad) generates
miRNAs processed from the longer structured virus-associated RNAs, VA-RNA I and II. The
VA-RNAs themselves are described to suppress the cellular RNA interference (RNAi) pathway
by interfering with the activity of Dicer [22]. For the VA-RNA derived miRNAs (mivaRNAs)
cellular target genes were identified, some of which are involved in the regulation of cellular
gene expression [23, 24]. The exact role of the Ad mivaRNAs for the adenovirus life cycle has
not yet been defined. Most members of the herpesvirus family encode clusters of miRNAs,
which are differentially expressed during latent or lytic infection. During HSV1 latency only a
single abundant viral transcript is expressed. This latency-associated transcript (LAT) repre-
sents a non-coding RNA that serves as a precursor for several miRNAs [25], assumed regula-
tors of HSV1 latency. Of the 18 well described HSV1 miRNAs, a role during the herpesviral life
cycle has only been determined for three: miR-H2 and miR-H6 repress the major HSV1 tran-
scriptional activators ICP0 and ICP4, respectively, and thus maintain the latent state [25], and
miR-H4 has been shown to target the HSV1 pathogenicity factor ICP34.5 [26]. For certain
Small RNA-Seq of AAV2-Infected Cells
PLOS ONE | DOI:10.1371/journal.pone.0161454 September 9, 2016 2 / 22
competing interests: RH is an inventor of patents
related to AAV vector technology and owns equity in
a company that is commercializing AAV for gene
therapy. This does not alter our adherence to PLOS
ONE policies on sharing data and materials.
herpesviruses microRNA-offset RNAs have been identified, whose functions are presently
unknown [27, 28].
AAV represents one of the very few DNA viruses for which small regulatory RNAs have not
yet been described. Its bipartite life cycle combined with the hairpin-structured AAV-ITRs
reminiscent of the structure of miRNA precursors led to the hypothesis that small RNA species
with regulatory function might be expressed by AAV as well. In the first comprehensive Illu-
mina-based small RNA-Seq analysis of AAV-infected cells we discovered and validated several
classes of previously unknown small non-coding RNAs.
Materials and Methods
Cell culture and viruses
HEK 293 and HeLa cells were obtained over 30 years ago from ATCC and passaged since as
described [29]. Human adenovirus type 2 (Ad2) was propagated and quantified in 293 cells.
The HSV1 KOS strain was produced in Vero cells and titrated by plaque assay.
AAV2 production, purification and quantification
For AAV2 production HEK 293 cells were seeded at 30% confluency and transfected 24 hours
later with pTAV2-0 [30] and pHelper as described [2]. AAV2 was purified from benzonase-
treated, cleared freeze-thaw supernatants by one-step AVB sepharose affinity chromatography
and quantified by Light-Cycler PCR as described [31] with primers specific for AAV2 rep
(Rep2-Fwd: AGAAGGAATGGGAGTTGCCG and Rep2-Rev: TCTGACTCAGGAAACGTCCC).
AAV2 infectious titers were determined by end point dilutions on Ad2 infected HeLa cells [32].
Virus infection
HeLa cells were seeded at a density of 30% and infected 20 hours later with AAV2 wild-type
(MOI 250), Ad2 (MOI 25) or HSV1 (MOI 10), or indicated combinations thereof.
RNA extraction
Total RNA was extracted 8 hpi and 27 hpi from AAV2 infected cells in presence or absence of
HSV1 or Ad2, respectively. Total RNA was isolated using TRIzol Reagent (Ambion) according
to the manufacturer’s protocol. Subsequently, RNA samples were treated with RNase-free
Turbo DNase (Ambion), followed by phenol-chloroform extraction and precipitation. RNA
quality and integrity was verified on 0.8% agarose gels and on bioanalyzer (Agilent). Total
RNA samples of proven high quality were used for small RNA library generation and Northern
blot analysis.
Northern blot analysis
For electrophoresis 15% polyacrylamide gels containing 8 M urea and 0.5x MOPS running
buffer (10x MOPS is 200 mMMOPS, 50 mM sodium acetate and 10 mM EDTA, pH 7.0) were
used. Prior to loading of the samples the gel was pre-run at 100 V for 30 min. RNA samples
were treated using the FDF-PAGE method as described [33]. In short, equal amounts of total
RNA (5 μg to 25 μg per lane) in a volume of 4 μl were mixed with 11 μl FDF buffer (2.75 μl
formaldehyde (37%), 7.5 μl formamide (>99.5%) and 0.75 μl 10x MOPS buffer), incubated at
55°C for 15 min and subsequently mixed with 2 μl of 10x dyes (0.05% [w/v] xylene cyanol and
0.05% [w/v] bromphenol blue in nuclease-free water) before loading. In addition 1 μl of micro-
RNA ladder (NEB) and 5 μl of low range ssRNA ladder (NEB) were loaded onto the gel. Electro-
phoresis was run at 150–200 V until the bromphenol blue dye reached about 2 cm at the bottom
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of the gel. After electrophoresis, gels were stained in ethidium bromide (10 μg/ml) to visualize
the RNA size markers. RNAs were transferred to a positively charged nylon membrane (Gen-
eScreen Plus, PerkinElmer) at 1 mA/cm2 for 1.5 h or overnight by electroblotting, and cross-
linked by UV (Stratagene) or EDC for 2 h at 60°C as described [34]. The membranes were pre-
hybridized for 2 h in pre-warmed hybridization buffer (5x SSC [10x SSC is 1.5 M NaCl plus 0.15
M sodium citrate], 1% SDS and 1x Denhardt´s Solution [100x Denhardt´s Solution is 2% [w/v]
BSA, 2% [w/v] Ficoll 400 and 2% [w/v] Polyvinylpyrrolidone]). DNA-oligonucleotides (MWG
Eurofins) or DNA/LNA-oligonucleotides (Exiqon) [35] with sequences complementary to
sRNAs (see S1 Table) were 5’ end labeled with [γ-32P]-ATP (Hartmann Analytic), and purified
on a Bio-Gel P-10 column (Bio-Rad). Membranes were hybridized for 16 hours at 37°C or at
55–65°C with the labeled DNA- or DNA/LNA-probes, respectively. Subsequently, membranes
were washed three times for 10 min with low stringency buffer (2x SSC / 0.1% SDS), followed by
two washing steps at higher stringency (1x SSC / 0.1% SDS) for 5 min at 37°C or at 55–65°C for
membranes hybridized with DNA- or DNA/LNA-probes, respectively. Membranes were
exposed to X-ray films between intensifying screens at -80°C overnight or longer.
Co-immunoprecipitation (Co-IP) of human argonaute protein complexes
Co-immunoprecipitation was carried out as described [23]. In brief, uninfected or infected
HeLa cells were washed twice with ice-cold PBS 27 hpi and lysed in cell lysis buffer containing
25 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2 mMMgCl2, 0.5% Nonidet P40, 5 mM dithiothrei-
tol (DTT), protease inhibitor (cOmplete Tablets, Mini Easypack, Roche) and 40 U/ml RNase
inhibitor (Recombinant RNasin Ribonuclease Inhibitor, Promega) for 30 min at 4°C on an
overhead tumbler. Cell debris was removed by centrifugation at 20,000 g for 30 min at 4°C. For
co-immunoprecipitation, 100 μl Protein G-Agarose beads (Roche) per preparation were
washed three times in ice-cold nuclease-free PBS and subsequently resuspended in 1 ml nucle-
ase-free PBS supplemented with protease inhibitor cocktail. 15 μg of anti-pan Ago mAb clone
2A8 (Merck Millipore) or anti-Rep mAb 76–3 (Progen) were added to the pre-washed beads,
respectively, and incubated for 6 hours at 4°C under constant rotation. Antibody-coupled
beads were blocked at 4°C over night in blocking solution consisting of nuclease-free PBS con-
taining 1.2 mg/ml BSA, 0.6 mg/ml yeast tRNA (Roche) and protease inhibitor cocktail. The
beads were washed three times in ice-cold blocking solution and once with cell lysis buffer. For
immunoprecipitation, the cell lysates were incubated with the prepared antibody-coupled
beads under constant rotation at 4°C over night. Following, the beads were washed twice with
cell lysis buffer supplemented with BSA and tRNA, three times with high salt washing buffer
(25 mM Tris-HCl (pH 8.0), 900 mM NaCl, 2 mMMgCl2, 1% Nonidet P40, 5 mM DTT, prote-
ase inhibitor cocktail, 40 U/ml RNase inhibitor, BSA and tRNA) and twice with low salt wash-
ing buffer (25 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2 mMMgCl2, 0.05% Nonidet P40, 5 mM
DTT, protease inhibitor cocktail, 40 U/ml RNase inhibitor, BSA and tRNA). Co-immunopre-
cipitated RNAs were isolated from the beads using the TRIzol Reagent (Ambion) followed by
RNA precipitation and purification.
Small RNA library preparation and Illumina Sequencing
1 μg of each of the eight different total RNA samples (cells, AAV2, AAV2 + HSV1, HSV1
extracted 8 hpi and cells, AAV2, AAV2 + Ad2, Ad2 extracted 27 hpi) were subjected to small
RNA library generation using the TruSeq Small RNA Sample Prep Kit according to the manu-
facturer’s protocol (Illumina). Briefly, after ligation of the RNA 3’- and the RNA 5’ adapter,
total RNA samples were reverse transcribed to cDNA libraries and subsequently PCR-ampli-
fied. The PCR products were run on 6% PAGE gels and bands of adapter-ligated DNA libraries
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between 145 and 160 basepairs (bp) were excised from the gel and purified. These bands corre-
spond to RNAs of a length of approximately 20 to 35 nucleotides. Subsequently, the libraries
were validated by bioanalyzer, pooled and sequenced on a HiSeq 2000 platform (multiplexed
1x51+7).
Processing of sequencing reads
The sequencing reads were demultiplexed and the sequencing adapters were removed. Reads
shorter than 16 bp were discarded; the remaining reads were mapped without mismatch to the
human genome (hg19), transcriptome (generated from RefSeq annotations) and pre-miRNA
sequences (downloaded from the miRBase [36], http://www.mirbase.org) using Bowtie [37].
The unmapped reads were further aligned to HSV1 (accession number NC_001806.1), Ad2
(accession number AC_000007.1) and AAV2 (accession number NC_001401.2) reference
genomes. Additional sequence mapping was performed gradually allowing zero, one and two
mismatches (see S2 Table).
Database of microRNAs, secondary structure prediction and miRNA
target prediction
Known human, HSV1 and Ad microRNAs were obtained from miRBase, the database of
microRNAs (http://www.mirbase.org/). For secondary structure prediction of possible precur-
sor RNAs the Vienna RNAfold WebServer was used (http://rna.tbi.univie.ac.at/cgi-bin/
RNAfold.cgi). To search for putative target sites of described human miRNAs the miRNA tar-
get prediction tool “Target Scan” was applied (http://www.targetscan.org).
Results
Small RNA-Seq library preparation
To identify AAV2-derived small RNA species we performed Illumina small RNA next genera-
tion sequencing. HeLa cells were infected with AAV2 alone or co-infected with AAV2 and the
helper viruses Ad2 or HSV1, respectively. Uninfected, Ad2 and HSV1 infected cells served as
controls. Total RNAs were extracted at 8 hpi after HSV1 infection or 27 hpi after Ad2 infection.
Together, two sets of four total RNA samples were generated, each representing the latent and
lytic AAV2 infection state including controls. All samples contained highly intact RNA as vali-
dated by bioanalyzer displaying RNA integrity numbers (RIN) higher than 8.90. Using the Illu-
mina TruSeq small RNA sample preparation kit, libraries of RNAs with sizes between 20 to 35
nucleotides were generated. The integrity of the libraries was re-checked immediately prior to
sequencing on the Illumina HiSeq 2000 platform.
Illumina small RNA-Seq next generation sequencing
For each data set between 18.0 and 24.9 million RNA reads were obtained by Illumina small
RNA-Seq analysis (Table 1). The majority of these reads (>88%) corresponded to RNAs with a
size of at least 16 nucleotides (nt). Based on these, a total of 50 to 85% could be assigned to
sequences of the human genome without allowing any mismatch. Due to the inherent error
rate of Illumina sequencing, higher numbers of reads could be assigned to the human and viral
genomes when allowing one and two mismatches (S2 Table). While the numbers per mapped
read increased, this did not lead to the detection of further small RNAs. In all of the 8 data sets
a significant portion of reads could be mapped to known human miRNAs (Table 1). In the
absence of a helper virus very low numbers of small AAV2-specific RNA reads were detectable
in AAV2 infected cells. Their numbers were increased by more than 200-fold in presence of
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HSV1 or Ad2 accounting for 0.7 to 1.4% of total small RNA reads displaying at least 16 nt in
size (Table 1). The consistently lower read numbers in the HSV data set may be due to the
short HSV replication cycle and consequently earlier time point of cell harvest (8 hpi versus 27
hpi). Similar to AAV2, HSV1 showed a low number of specific small RNAs (0.5 to 0.6% of
total reads), whereas the number of small RNAs mappable to Ad2 was significantly higher
(14.1 to 22.0% of total reads). On the other hand, Ad2-specific read numbers were significantly
reduced in presence of AAV2, presumably reflecting the known inhibitory effect of AAV on
adenovirus replication [38, 39]. Furthermore, in the presence of Ad2 human miRNAs were
slightly less abundant compared to those in the other data sets (Table 1) confirming the recent
finding that certain human miRNAs are dramatically deregulated during adenovirus infection
[40]. In addition, adenovirus was shown to block the RNAi processing machinery in order to
generate its own miRNAs late during infection [22]. In the following all further analyses were
performed using zero mismatches per mapped read (Table 1).
Small RNA read mapping to the AAV2 (+) and (-) strand
The population of AAV2-specific small RNA reads for each data set was mapped to the wild-
type AAV2 genome. For a better overview RNA reads were initially counted in closed intervals
of 10 nucleotides. In the presence of Ad2, AAV2 infected cells showed a high number of small
RNAs located within the ITRs (Fig 1A). Since small RNAs located in the ITRs cannot be
mapped unambiguously to one ITR, they were assigned to either end. A significant amount of
reads mapped to the region opposite of the p5 promoter (anti-p5) on the AAV (-) strand and
to a region close to the p40 promoter on the AAV (+) strand (Fig 1A). The transcription profile
of small AAV2 RNAs (27 hpi) was comparable in cells with and without Ad2 infection, but the
absolute read numbers differ by a factor of around 200. However, no accumulation of p40 pro-
moter-associated reads could be observed in the absence of Ad2 (Fig 1B). In the presence of
HSV1 the AAV transcription profile of small RNAs was different to that observed in the
Table 1. Small RNA-Seq—Assignment of the reads to the species fromwhich they originate.
Data set Total no. of
reads
No. (%) of
reads 16 nt
No. (%) of human
readsa
No. (%) of small reads assigned to: No. (%) of
unknown readsbHuman
miRNAs
AAV2 Ad2 HSV1
Cells (27 hpi) 19,395,459 17,429,392 (89.9) 14,653,485 (84.1) 4,793,871
(27.5)
17 (<0.1) 348 (<0.1) 6 (<0.1) 809,469 (4.6)
AAV2 (27 hpi) 18,085,432 16,228,519 (89.7) 13,331,538 (82.1) 5,840,779
(36.0)
1,193
(<0.1)
1,209 (<0.1) 9 (<0.1) 1,037,657 (6.4)
AAV2 + Ad2
(27 hpi)
21,333,021 18,814,505 (88.2) 11,238,151 (59.7) 3,307,157
(17.6)
270,577
(1.4)
2,644,519
(14.1)
12 (<0.1) 2,142,730 (11.4)
Ad2 (27 hpi) 24,841,074 24,202,341 (97.4) 12,151,399 (50.2) 5,129,522
(21.2)
24 (<0.1) 5,332,713
(22.0)
14 (<0.1) 6,079,458 (25.1)
Cells (8 hpi) 21,851,591 20,985,998 (96.0) 17,475,849 (83.3) 6,899,774
(32.9)
15 (<0.1) 286 (<0.1) 13 (<0.1) 2,644,242 (12.6)
AAV2 (8 hpi) 20,375,107 20,022,269 (98.3) 16,464,292 (82.2) 7,551,710
(37.7)
160 (<0.1) 449 (<0.1) 10 (<0.1) 3,204,520 (16.0)
AAV2 + HSV1
(8 hpi)
23,031,470 20,904,023 (90.8) 16,445,457 (78.7) 7,202,911
(34.5)
146,807
(0.7)
3,933 (<0.1) 108,860
(0.5)
2,071,519 (9.9)
HSV1 (8 hpi) 22,391,766 20,895,686 (93.3) 16,671,702 (79.8) 9,745,884
(46.6)
14 (<0.1) 326 (<0.1) 124,055
(0.6)
2,603,509 (12.5)
aIncluded are reads mapped to the human genome, transcriptome and miRNAs.
bIncluded are reads 16 nt that were unmappable during sequence mapping allowing zero mismatches.
doi:10.1371/journal.pone.0161454.t001
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Fig 1. Small RNA-Seq: Readmapping of small AAV2-specific RNAs to either strand of the genome. (A) Mapping of AAV2-specific
reads identified by the small RNA-Seq analysis in AAV2/Ad2 co-infected HeLa cells 27 hours p.i. (hpi). The AAV2 genome scale is displayed
in the center. Reads mapped to the AAV2 (+) strand are displayed above and those mapped to the AAV2 (-) strand below the genome, read
counts are shown in intervals of 10 nucleotides. The ITR regions are highlighted in turquoise. The positions of the known AAV promoters on
either strand are indicated by arrows. The total read count is indicated. Note the ambiguous assignment of reads mapping to the ITRs. (B)
Mapping of small AAV2-specific reads in AAV2 infected HeLa cells 27 hpi, displayed as in (A). (C) Mapping of small AAV2-specific reads in
AAV2/HSV1 co-infected HeLa cells 8 hpi, displayed as in (A). (D) Mapping of small AAV2-specific reads in AAV2 infected HeLa cells 8 hpi,
displayed as in (A). Note the different scales of read counts in (A to B) and (C to D).
doi:10.1371/journal.pone.0161454.g001
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presence of Ad2 (Fig 1C). Neither the ITR nor the AAV (-) strand showed an accumulation of
small RNA reads, but similarly to Ad2 co-infected cells, there was indication of a RNA hotspot
close to the p40 promoter (compare Fig 1A and 1C). Additional small RNA reads were located
downstream of the p40 promoter (Fig 1C). RNA harvested from AAV infected cells (8 hpi)
showed hardly any AAV2-specific reads (Fig 1D). Obviously, AAV transcription in the absence
of a helpervirus starts delayed (compare Fig 1A to 1B and 1C to 1D).
Mapping of small RNA reads to the Ad2 and HSV1 genomes
Comparative analysis of Ad2 and HSV1 as helper viruses for productive AAV2 replication
allowed the validation of small RNA-Seq data by analysis of known Ad or HSV encoded miR-
NAs, respectively. Indeed, the majority of Ad2-specific small RNA reads (>95%) could be
assigned to the adenoviral mivaRNAs in the absence, as well as in the presence of AAV2 (Fig
2A and 2B). These small RNAs, processed from the longer structured VA RNA I and II, are
expressed in lytic, as well as in persistently infected cells [41, 42]. Co-infection with AAV2
reduced the numbers of mivaRNA I and II by half, likely explained by the repressive activity of
co-replicating AAV2. Similarly, many of the HSV1-specific small RNA reads could be assigned
to known HSV1 encoded miRNAs in the data sets of HSV1 infected cells in the presence or
absence of AAV2 (Fig 2C and 2D). Since small RNA reads within repeat regions cannot be
unambiguously mapped, they were assigned to either HSV repeat as applied here for the small
AAV RNAs. Prominent hotspots could be attributed to the miRNAs miR-H4-3p and miR-H6-
3p located within the HSV1 repeat region IRL (TRL) (Fig 2C and 2D). Furthermore,
HSV1-miR-1 and -2 were moderately expressed with 300 and 700 reads, respectively, whereas
HSV1-miR-3, -5, -11, -12 and -16 were hardly detectable (<100 reads). HSV miRNAs are dif-
ferently expressed during latent and lytic infection in highly susceptible cell types [27]. In HeLa
cells used here, a prominent small RNA hotspot was detected at HSV1 genome position
132,142 [+] or 146,091 [–] (Fig 2C and 2D, named IRS-HS / TRS-HS). This hotspot has also
been reported in another study during early lytic HSV1 infection just recently [43].
Detailed mapping of AAV2-specific small RNAs
For more precise mapping of the small AAV2-specific RNAs the regions with high read counts
were enlarged to single nucleotide level in the data set of AAV2/Ad2 co-infected cells (Fig 3A).
The 5’ end of any small RNA was defined as starting nucleotide used henceforth as nomencla-
ture for these RNAs. Even on a single nucleotide level hotspots of small RNAs were detected.
The threshold was arbitrarily set to 3,000 reads, which is approximately 100-fold above back-
ground. Only small RNAs above this threshold were defined as hotspots and analyzed further.
Four hotspots were located within the AAV-ITRs, sR-1 and sR-108 on the AAV (+) strand, and
sR-125 and sR-141 on the AAV (-) strand (Fig 3A). Due to the ambiguous character of the ITRs
sR-1 on the AAV (+) strand is equivalent to sR-125 on the AAV (-) strand with 3,170 reads (Fig
3B). Furthermore, sR-1, sR-108 and sR-141 can be mapped to either ITR on the AAV (+) or (-)
strand (see S3 Table). In fact, sR-108 represented one of the two most abundant small RNAs
with 12,002 read counts (Fig 3B) with a predominant mean read length of 21 nt (Fig 3C). The
other prominent hotspot, displaying sR-271, was located downstream of the newly identified
anti-p5 promoter on the AAV (-) strand [11] with 12,737 reads and showed varying read
lengths between 16 and 23 nt (Fig 3C). Furthermore, additional minor hotspots clustered in that
region (Fig 3A and 3B). Another hotspot, displaying sR-1862, was located just downstream the
transcription start site (TSS) of the p40 promoter with 3,780 read counts. This particular small
RNA showed a read length between 18 and 19 nt (Fig 3C). All hotspots displayed an average
read length between 19 and 22 nt, typically seen for small non-coding regulatory RNAs
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(Fig 3B). The overall expression of the AAV2-specific small RNAs was comparable to that of
HSV1 small RNAs but lower than that of Ad mivaRNAs. For AAV2/HSV1 infected cells the
small AAV2-specific reads were of low abundance and mostly below the threshold of 3,000
reads. A list of the top hundred AAV-specific small RNAs in the presence of the helper viruses
Fig 2. Small RNA-Seq: Mapping of small RNA reads to the genomes of Ad2, or HSV1. (A) Mapping of Ad2 reads identified by the
small RNA-Seq analysis to the Ad2 genome in AAV2/Ad2 co-infected HeLa cells 27 hpi. The Ad2 genome scale is displayed in the
center. Reads mapped to the Ad2 (+) strand are displayed above and to the Ad2 (-) strand below, read counts are shown in intervals of 10
nucleotides. Terminal repeats flanking the adenoviral genome are highlighted in turquoise. Reads assigned to the described adenoviral
mivaRNAs I and II are indicated by arrows. The total read count of small RNAs is indicated. (B) Mapping of small Ad2 reads in Ad2
infected HeLa cells 27 hpi, displayed as in (A). (C) Mapping of HSV1 reads identified by the small RNA-Seq analysis to the HSV1 genome
(KOS strain) in AAV2/HSV1 co-infected HeLa cells 8 hpi, displayed as in (A), but in intervals of 100 nucleotides. Terminal (TR) and
internal repeat (IR) regions within the HSV1 genome are highlighted in shades of turquoise. Small RNAs of high read frequencies were
assigned to known HSV1miRNAs according to miRBase. A small RNA with very high read counts was designated as IRS-HS / TRS-HS
due to its location within these repeat regions. Note the ambiguous assignment of reads mapping to the repeat regions. (D) Mapping of
small HSV1 reads in HSV1 infected HeLa cells 8 hpi, displayed as in (C). Note the different scales of read counts in Ad2 infected cells (A,
B) and HSV1 infected cells (C, D).
doi:10.1371/journal.pone.0161454.g002
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Fig 3. Small RNA-Seq: Detailed mapping of small AAV2-specific reads to both strands of the genome. (A) Detailed mapping of small
AAV2-specific reads in regions of high read frequencies in AAV2/Ad2 co-infected cells from Fig 1A. A schematic representation of the AAV2
genome is displayed in the center. Read assignments to the (+) strand are presented above and to the (-) strand below the genome, with read
counts displayed at single nucleotide level. A horizontal dashed line marks the threshold value set to 3,000 reads. Any small RNA (sR) above
3,000 read counts was defined as hotspot candidate, designated according to the 5’ starting nucleotide. Different genomic regions of the
AAV2-ITRs (highlighted in turquoise) are separated by vertical dashed lines. Complementary regions of the hairpin-structured ITR are
indicated by letters, e.g. A, A’; D, D’. Promoters on the AAV2 (+) or (-) strand are indicated by arrows. (B) Summary of small RNA hotspot
candidates on the AAV2 genome, displayed in (A), designated according to their starting nucleotide (5’ end). Average read lengths are shown
for the small RNAs. (C) Depicted are the detailed small RNA read length distributions for sR-108, sR-271 and sR-1862. Small RNA hotspots
highlighted in red were validated further.
doi:10.1371/journal.pone.0161454.g003
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Ad and HSV, respectively, is given in S3 Table, which includes data of genomic location, read
counts, median read length and sequence of the respective small AAV RNAs.
Validation of the AAV2-specific small RNA hotspots
To confirm the presence of AAV2-specific small RNAs by an alternative method, total RNA was
harvested from AAV2 infected and AAV2/Ad2 co-infected HeLa cells and respective controls.
RNA samples treated with RNase-free DNase were analyzed on Northern blots with specific
probes directed against the most prominent AAV2-specific small RNAs. As internal controls, the
human miRNA hsa-let-7a-1 and the splicosomal U6-snRNA were detected in all RNA extracts
(Fig 4A) showing the high quality of the RNA samples. The highly abundant sR-108 located in
the ITR of the AAV (+) strand was detected with a specific DNA probe (Fig 4A) and also with a
specific DNA/LNA probe (Fig 4B) only in extracts harvested from AAV2/Ad2 co-infected cells,
but not in AAV2/HSV1 co-infected cells (Fig 4A), which is in agreement with the data of the
RNA-Seq analysis described above. The size of the detected bands was in the range of approxi-
mately 20–30 nt. Furthermore, larger RNA fragments with sizes of approximately 100 nt, 200 nt,
250 nt and above were visible (Fig 4B). Similar bands were also detected with a DNA probe, spe-
cific to sR-271, located on the AAV (-) strand (compare Fig 4C and 4B). Furthermore, a very
faint band at a size around 25 nt was visible, corresponding to sR-271 (Fig 4C). In agreement
with the varying read length distribution of sR-271 described above (see Fig 3C), it was not sur-
prising that no sharp band could be detected in the gel for this small RNA. In contrast to sR-108
and sR-271, no AAV2-specific small RNA indicative of sR-1862 could be detected using a DNA/
LNA probe (Fig 4D). The failure to validate sR-1862 by Northern blot analysis might be due to
its 3- to 4-fold lower abundance compared to sR-108 and sR-271 (see Fig 3), probably lower than
the detection limit of the used method. Unexpectedly, either probe (DNA and DNA/LNA)
detected a strong Ad2-specific band of> 300 nt (Fig 4D). Even with highly stringent hybridiza-
tion and washing conditions the bands persisted. An alignment to the Ad2 genome did not show
a target sequence of the designed AAV2 probe. None of the AAV2-specific small RNAs was
detected upon HSV co-infection, which was anticipated from their low abundance in RNA-Seq.
Detection of human argonaute protein (Ago) co-immunoprecipitated
RNAs
To determine whether sR-108, sR-271 and sR-1862 represent functional miRNAs, their loading
into the RNA-induced silencing complex (RISC) was studied. Ago2 is a component of RISC,
which binds the mature miRNA and thus enables mRNA target recognition. We performed
co-immunoprecipitations (Co-IP) of human Ago2 complexes with total RNAs from infected
cells, using an antibody that detects the human argonaute proteins 1 to 4. Subsequently, the
RNAs isolated from the precipitates were analyzed on Northern blots using probes directed
against the AAV2-specific small RNAs sR-108, sR-271 or sR-1862, respectively. Probes
directed against the human miRNA hsa-let-7a and the cellular U6-snRNA, a component of the
splicosome, were used as controls. The human miRNA hsa-let-7a-1 could be detected in all
total RNA and Co-IP RNA extracts, with the exception of co-immunoprecipitated RNAs in
lane 7 for which an unrelated control antibody was used (Fig 5). In the AAV/Ad2 co-infected
and Ad2 infected Co-IPs, hsa-let-7a-1 was reduced (Fig 5, lanes 6 and 8), in agreement with
data that adenovirus down-regulate human hsa-let-7a [40] and blocks the RNAi pathway [22].
Since the U6-snRNA is not incorporated into RISC, it is only detectable in total RNA extracts
(Fig 5, lanes 1 to 4). In contrast to hsa-let-7a, AAV-specific small RNAs could not be detected
after immunoprecipitation of Ago2 complexes with any of the probes for sR-108, sR-271, or
sR-1862 (Fig 5). Obviously, the identified small RNAs do not represent functional miRNAs.
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Instead, these RNAs may belong to another class of small non-coding regulatory RNAs, or are
alternatively processed.
Alignment of the small AAV2 RNAs to other AAV serotypes
To evaluate the relevance of the newly identified small RNAs the genomes of AAV serotypes 1
to 7 were aligned and compared to the AAV2 sequences of sR-108, sR-271 and sR-1862 (S1
Fig). The small AAV2 RNAs sR-108 and sR-1862 showed a high degree of conservation among
the AAV serotypes, with the exception of AAV5, the most distantly related member. AAV2 sR-
271 on the AAV (-) strand displayed some variations from other AAV serotypes in the central
part of the small RNA.
Fig 4. Detection of AAV2-specific small RNAs by Northern blot analysis. (A) Northern blot analysis of
DNase treated total RNA extracts from HeLa cells, either none infected (Mock), or infected with AAV2, AAV2
and Ad2, AAV2 and HSV1, Ad2, or HSV1, harvested at the indicated time points. Total RNA extracts
separated on 15% PAA-Urea gels, transferred to a positively charged membrane were hybridized with
radiolabeled DNA probes directed against the depicted AAV2 small RNA sR-108, the human miRNA hsa-let-
7a, or the cellular U6-snRNA, respectively. To the right detected small RNAs are indicated. (B) Experimental
procedure as in (A) but RNAs were detected by a radiolabeled DNA/LNA probe directed against the AAV2
small RNA sR-108. (C) Experimental procedure as in (A) but RNAs were detected by a radiolabeled DNA
probe directed against the AAV2 small RNA sR-271. (D) Experimental procedure as in (A) but RNAs were
detected by a radiolabeled DNA/LNA probe targeting the AAV2 small RNA sR-1862. To the left, the
molecular sizes of the bands of the miRNA ladder and the ssRNA ladder, respectively, are depicted.
doi:10.1371/journal.pone.0161454.g004
Small RNA-Seq of AAV2-Infected Cells
PLOS ONE | DOI:10.1371/journal.pone.0161454 September 9, 2016 12 / 22
Effect of AAV2 on the expression levels of cellular miRNAs
To assess whether AAV2 infection has an effect on the cellular miRNA expression profile, the
read counts of 979 cellular miRNAs were determined, that are listed in the miRNA database
(miRBase) [44]. Their expression levels determined by small RNA-Seq in AAV2 infected cells
Fig 5. Human argonaute protein (Ago) co-immunoprecipitated RNAs of AAV2 infected cells.Northern
blot analysis of DNase treated total RNA extracts or co-immunoprecipitated Ago-RNA complexes as
indicated from HeLa cells, either mock infected, or infected with AAV2, AAV2 and Ad2, or Ad2, harvested 27
hpi. For co-immunoprecipitation, cell lysates were incubated over night with anti-pan Ago mAb or anti-Rep
mAb 76–3 antibodies coupled to protein G agarose beads, respectively, as outlined in the methods. Northern
blot analysis of purified RNAs was performed as described in Fig 4, with radiolabeled DNA probes directed
against the AAV2-specific small RNAs sR-108, sR-271 or sR-1862, the human miRNA hsa-let-7a or the
cellular U6-snRNA, respectively, as indicated. Note that instead of the human anti-pan Ago antibody an
unrelated antibody (anti-Rep76-3) was used in lane 7 for co-immunoprecipitation.
doi:10.1371/journal.pone.0161454.g005
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8 hpi, 27 hpi were compared to those in uninfected cells (Fig 6). In addition, cellular miRNA
regulation by lytic AAV replication in the presence of either helper virus was analyzed (S2 Fig).
In the light of known extensive effects of either Ad or HSV on host cell transcription, miRNA
effects cannot be readily attributed to lytic AAV infection. In the case of AAV infection alone
the majority of cellular miRNAs were unaltered within a 2- to 5-fold range of regulation. One
single human miRNA, hsa-mir-3687, was down-regulated slightly above 5-fold upon AAV
infection (Fig 6A and 6B). To evaluate the significance of hsa-mir-3687 regulation the program
"TargetScan" for miRNA target prediction was used and putative target genes were searched
[45]. Eight human genes were predicted as potential targets of hsa-mir-3687, with MTA2
(metastasis associated 1 family, member 2) as the most likely candidate. However, the RNA
expression levels of the predicted cellular target genes retrieved from our previously total
RNA-Seq analysis performed under the same conditions were unaltered. Thus, AAV infection
even at high MOIs does not significantly affect cellular miRNAs. This result extends earlier
findings from microarray-based RNA screens demonstrating that AAV infection has no major
effect on host mRNA expression [46]. The absence of miRNA induced transcriptional effects
upon AAV infection further underlines the long-held notion that AAV infection is largely
apathogenic.
Discussion
In this report we present the first comprehensive analysis of AAV-encoded small RNAs from
infected cells using Illumina small RNA-Seq. Whereas the cellular miRNA profile was largely
unchanged by AAV infection, previously unrecognized small AAV RNAs were detected. Their
abundance, AAV serotype conservation and predominant localization in close proximity to the
established AAV promoters, p40 and p5, calls for roles as transcriptional regulators during
latency and active replication.
Putative generation of the small AAV2 RNAs
Based on their location we postulate that sR-108 and sR-271 are generated from the recently
identified anti-p5 promoter, whereas sR-1862 is expressed from the p40 promoter. We recently
detected the novel anti-p5 promoter on the AAV (-) strand [11]. The previously performed
total RNA-Seq designed to detect long AAV transcripts led to its discovery.
In order to initiate transcription, second-strand synthesis of the AAV ssDNA genome is
required [47]. Thereby a monomer turnaround structure (mT) is generated with the ITR con-
nected to both complementary strands (Fig 7A). RNA polymerase can proceed through the
ITR as shown recently for AAV mutants lacking the authentic polyA signal [48]. By continuing
transcription on the opposite AAV strand double-stranded RNA can be formed (Fig 7A) as
shown recently for the related parvovirus, minute virus of mice (MVM) [49]. The postulated
AAV-ITR precursor transcript would comprise the two small RNAs, sR-108 and sR-271. Alter-
natively, RNA transcription could also be initiated independently at the ITR to yield the RNAs
on the AAV (+) strand (sR-108). Transcripts mapping to the AAV2-ITRs have been reported
previously [11, 50, 51], but neither 5’ ends nor function have been further investigated. For
AAV5, the 5' end of the analogous transcripts could be mapped to nucleotide position 142
[52]. Small RNAs are often processed from longer precursor RNAs by various enzymes [53].
Due to the structure of the ITR the RNA product will automatically adopt a T-hairpin loop sec-
ondary structure (Fig 7A and 7B). An additional hairpin loop is generated at the terminal reso-
lution site (trs) during Rep-dependent, strand-specific nicking of the AAV genome required to
resolve the ssDNA genomes during AAV DNA replication [54, 55]. Recently, AAV2 Rep was
shown to also bind to ITRs composed of RNA [48]. Nicking of the trs RNA-bound Rep, would
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Fig 6. Effect of AAV2 infection on the expression of cellular miRNAs. (A) The expression levels of 979
described cellular miRNAs were analyzed by small RNA-Seq analysis in AAV2 infected versus uninfected
HeLa cells at 27 hpi. Dots near the red line represent equally expressed miRNAs in both data sets, the solid
gray lines mark 2-fold and the dashed gray lines 5-fold up- or down-regulation of miRNAs. The most highly
up- or down-regulated miRNAs were highlighted and specified. Cellular miRNAs below a level of 100 read
counts, within the dashed square, were not considered as representative. (B) Expression level of 979
described cellular miRNAs in AAV2 infected versus uninfected HeLa cells 8 hpi, displayed as in (A).
doi:10.1371/journal.pone.0161454.g006
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result in the here-described small RNAs starting at nucleotide position 1 or 125, respectively
(Fig 3, sR-1 and sR-125). Furthermore, genome-wide AAV integration analysis implied that
Rep-induced nicking within the human genome does not necessarily require a trs adjacent to
the Rep binding element (RBE) [2], leaving the possibility of Rep endonucleolytic attack at
other sites. Similar to the ITR, the region near the anti-p5 promoter potentially allows forma-
tion of a RNA secondary structure (Fig 7C). The sequence of sR-271 partially overlaps with the
p5 RBE and with the p5 TATA-box on the complementary strand. Since binding of Rep was
Fig 7. Model for the putative generation of the AAV2 small RNAs derived from the ITR and secondary structure formation. (A) A
model for the putative generation of AAV2-specific small RNAs located within and close to the ITR is given. RNA transcription is initiated
from the previously identified anti-p5 promoter on the AAV2 (-) strand. The RNA polymerase reads through the AAV2-ITR generating a
transcript (highlighted in blue) that reforms the T-shape structure of the ITR. Furthermore, this transcript is able to form additional hairpin
loops, which might be recognized by specific processing enzymes that generate the small RNAs sR-271 and sR-108 (highlighted in red).
(B) Secondary structure formation of the AAV2-ITR RNA. Depicted are the nucleotide positions of the (-) and in brackets of the (+) strand.
Indicated are the Rep binding element (RBE) framed in a dashed rectangle and the terminal resolution site (trs) at nucleotide position
-125 (+1). The newly identified small RNA sR-108 ranging from nucleotide position 108 to 128 on the AAV (+) strand is highlighted in red.
(C) Secondary structure formation of AAV2 RNA nucleotides 284 to 230 on the (-) strand. The newly identified small RNA sR-271 ranging
from nucleotide position 271 to 252 on the AAV (-) strand is highlighted in red. (D) Secondary structure formation of AAV2 RNA
nucleotides 1853 to 1897 on the (+) strand. The newly identified small RNA sR-1862 ranging from nucleotide position 1862 to 1881 on the
AAV (+) strand is highlighted in red. Secondary structure prediction was generated using RNAfold.
doi:10.1371/journal.pone.0161454.g007
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also shown on the RBE within the p5 promoter [56], Rep could also play a role in RNA process-
ing at this site.
Transcription of the small RNA sR-1862, located a few nucleotides downstream of the p40
TSS (nt 1853) could also lead to a secondary structure (Fig 7D). Recently, we have identified
this region as cis-regulatory element for the inhibition of recombinant adenovirus replication
[12]. Here we show by small RNA-Seq that p40-initiated transcripts although highly heteroge-
neous (Fig 3A), mostly represent sR-1862.
Interestingly, in all stem loop models the small RNAs, sR-108, sR-271 and sR-1862, span
sequences, which cover both sides of the stem loop including the terminal loop (Fig 7B–7D). It
is apparent that a processing mechanism other than the canonical miRNA processing pathway
is required to generate these small RNAs, since Dicer regularly removes the terminal loop for
miRNA generation.
Potential role of small AAV2 RNAs
Typically, virus encoded small non-coding RNAs are expressed either to support virus propa-
gation by generating beneficial conditions or to evade the cellular immune response [21]. The
majority of identified small RNAs represent microRNAs, but also other types of small RNAs
have been described [57–59]. For the parvovirus family including AAV, small RNAs have not
yet been reported. The here identified AAV-specific small RNAs are candidate regulators to
adapt to the environment of the host cell and/or co-replicating helper viruses.
The functional role of the small RNAs located within the ITRs are difficult to analyze by
genetic means, due to an overlap with elements required for DNA replication and/or virus
packaging [60, 61]. A series of previously described mutants in these elements showed a repli-
cation- and/or packaging-deficient phenotype [62, 63]. In addition to affecting the functions of
the AAV RBE and trs, the described mutations might have inadvertently abolished the genera-
tion of the newly detected small RNAs.
In a recent study we have shown that short transcripts initiated at the anti-p5 promoter are
generated [11]. Due to the heterogeneous character of these anti-p5 transcripts, we concluded
a mechanism reminiscent of divergent transcription from the AAV p5 promoter. In agreement
with that, small RNA-Seq showed several hotspots of small AAV2 RNAs initiated from the
anti-p5 promoter with various 5’ ends (Fig 3). The short antisense transcripts generated during
divergent transcription are believed to play a role in gene regulation by modulating promoter
activity [64]. Similarly, the here identified small RNAs sR-271, sR-262 and sR-241 might play a
role in AAV p5 promoter activity regulation.
In addition, a heterogeneous group of small AAV p40 promoter-associated transcripts has
been described [12]. A mechanism of RNA polymerase II pausing accompanied with the inhi-
bition of recombinant adenoviral replication was postulated. The here identified small RNA
sR-1862 starts next to the p40 TSS (nt 1853) and might be a likely candidate for adenoviral
inhibition. On the other hand, sR-1862 could also represent a transcription initiation RNA
(tiRNA). These small RNAs of 18 nt in size are typically located just downstream the TSS of
promoters and are generated by RNA polymerase II backtracking and cleavage by TFIIS. For
eukaryotes, tiRNAs have been described to be associated with highly expressed transcripts [65].
Driving the expression of AAV capsid proteins the AAV p40 promoter is extremely active late
during AAV replication.
The complex regulation of the AAV life cycle has not yet been fully unraveled, particularly
not in vivo. The discovery of the small AAV RNA species some derived from transcripts from
within the AAV-ITRs and associated with the major AAV promoters adds a new piece of infor-
mation to the unsolved puzzle of the AAV switch from latency to productive replication. In the
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absence of a suitable animal model to study the AAV biology in vivo, systems biology
approaches to study viral interaction with the host cell transcriptome offer detailed insight
onto potentially pathogenic host cell effects. Surprisingly and in contrast to most other virus
infections studied, AAV infection neither induces own miRNAs nor regulates host cell miRNA
levels to any significant extend. These findings are in line with earlier microarray-based cellular
mRNA analysis, where AAV infection showed virtually no regulation [46]. Together the data
underline the notion of AAV’s apathogenicity. Further studies particularly in vivo will be
required to unravel the role of the newly identified, obviously regulatory small AAV RNAs for
the AAV life cycle.
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